标题
FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid
作者
关键词
-
出版物
MEDICINAL RESEARCH REVIEWS
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2023-10-30
DOI
10.1002/med.21991
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Emerging Role of Protein O-GlcNAcylation in Liver Metabolism: Implications for Diabetes and NAFLD
- (2023) Ziyan Xie et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Tropifexor plus cenicriviroc combination versus monotherapy in non-alcoholic steatohepatitis: Results from the Phase 2b TANDEM study
- (2023) Quentin M Anstee et al. HEPATOLOGY
- Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial
- (2023) Arun J. Sanyal et al. NATURE MEDICINE
- Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism
- (2023) Jianjun Liu et al. npj Biofilms and Microbiomes
- Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
- (2022) Claudia D. Fuchs et al. Nature Reviews Gastroenterology & Hepatology
- Gut microbiota promotes cholesterol gallstone formation by modulating bile acid composition and biliary cholesterol secretion
- (2022) Hai Hu et al. Nature Communications
- FXR: structures, biology, and drug development for NASH and fibrosis diseases
- (2022) Si-yu Tian et al. ACTA PHARMACOLOGICA SINICA
- Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
- (2022) Naim Alkhouri et al. JOURNAL OF HEPATOLOGY
- Discovery of farnesoid X receptor and its role in bile acid metabolism
- (2022) John Y.L. Chiang et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Structure of bile acid transporter NTCP crucial for hepatitis B virus entry
- (2022) Jinta Asami et al. NATURE
- Bile acids and their receptors: modulators and therapeutic targets in liver inflammation
- (2022) Anna Bertolini et al. Seminars in Immunopathology
- IL ‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH
- (2022) Jun Xu et al. HEPATOLOGY
- Immunomodulatory functions of FXR
- (2022) Stefano Fiorucci et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR)
- (2022) Shipeng Zhou et al. BIOMEDICINE & PHARMACOTHERAPY
- Obeticholic acid aggravates liver injury by up-regulating the liver expression of osteopontin in obstructive cholestasis
- (2022) Jie Wang et al. LIFE SCIENCES
- Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway
- (2022) Jinbiao He et al. Frontiers in Pharmacology
- SIRT1 activation synergizes with FXR agonism in hepatoprotection via governing nucleocytoplasmic shuttling and degradation of FXR
- (2022) Shuang Cui et al. Acta Pharmaceutica Sinica B
- FXR Signaling-Mediated Bile Acid Metabolism Is Critical for Alleviation of Cholesterol Gallstones by Lactobacillus Strains
- (2022) Xin Ye et al. Microbiology Spectrum
- Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment
- (2022) Xiangyu Guo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH
- (2022) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Microbiota-induced lipid peroxidation impairs obeticholic acid-mediated antifibrotic effect towards nonalcoholic steatohepatitis in mice
- (2022) Aoxiang Zhuge et al. Redox Biology
- Bioequivalence and Pharmacokinetic Profiles of Generic and Branded Obeticholic Acid in Healthy Chinese Subjects Under Fasting and Fed Conditions
- (2021) Meng-Na Wang et al. Drug Design Development and Therapy
- A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis
- (2021) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- FXR agonists for NASH: How are they different and what difference do they make?
- (2021) Claus Kremoser JOURNAL OF HEPATOLOGY
- The critical role of FXR is associated with the regulation of autophagy and apoptosis in the progression of AKI to CKD
- (2021) Dong-Hyun Kim et al. Cell Death & Disease
- FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption
- (2021) Bethan L. Clifford et al. Cell Metabolism
- Farnesoid X receptor agonist for the treatment of chronic hepatitis B; a safety study
- (2021) Robin Erken et al. JOURNAL OF VIRAL HEPATITIS
- Mebhydrolin ameliorates glucose homeostasis in type 2 diabetic mice by functioning as a selective FXR antagonist
- (2021) Tong Zhao et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Th2 Modulation of Transient Receptor Potential Channels: An Unmet Therapeutic Intervention for Atopic Dermatitis
- (2021) Jianghui Meng et al. Frontiers in Immunology
- Fatty Liver Disease: Diagnosis and Stratification
- (2021) Yedidya Saiman et al. Annual Review of Medicine
- Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases
- (2021) Baoyi Guan et al. Acta Pharmaceutica Sinica B
- Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study
- (2021) Mary E. Rinella et al. JOURNAL OF HEPATOLOGY
- EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
- (2021) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Multicenter validation of association between decline in MRI‐PDFF and histologic response in nonalcoholic steatohepatitis
- (2020) Rohit Loomba et al. HEPATOLOGY
- SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
- (2020) Jiyu Zhou et al. Nature Communications
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- (2020) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
- (2020) Judith Aron-Wisnewsky et al. Nature Reviews Gastroenterology & Hepatology
- From NAFLD to MAFLD: when pathophysiology succeeds
- (2020) Herbert Tilg et al. Nature Reviews Gastroenterology & Hepatology
- Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus
- (2020) Kenji Kabashima et al. NEW ENGLAND JOURNAL OF MEDICINE
- Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis
- (2020) Adriana Carino et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Sphingosine 1-phosphate receptor-1 specific agonist SEW2871 ameliorates ANIT-induced dysregulation of bile acid homeostasis in mice plasma and liver
- (2020) Tingting Yang et al. TOXICOLOGY LETTERS
- ASBT(SLC10A2): A promising target for treatment of diseases and drug discovery
- (2020) Na Yang et al. BIOMEDICINE & PHARMACOTHERAPY
- Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
- (2020) Rohit Loomba et al. HEPATOLOGY
- The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC
- (2019) Michael Trauner et al. HEPATOLOGY
- Emodin Rescues Intrahepatic Cholestasis via Stimulating FXR/BSEP Pathway in Promoting the Canalicular Export of Accumulated Bile
- (2019) Xiao-Li Xiong et al. Frontiers in Pharmacology
- Obeticholic acid may increase the risk of gallstone formation in susceptible patients
- (2019) Samer Al-Dury et al. JOURNAL OF HEPATOLOGY
- REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis
- (2019) Vlad Ratziu et al. Contemporary Clinical Trials
- CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
- (2019) Paul J. Pockros et al. LIVER INTERNATIONAL
- Bile acid metabolites control TH17 and Treg cell differentiation
- (2019) Saiyu Hang et al. NATURE
- Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
- (2019) Mohammad Shadab Siddiqui et al. JOURNAL OF HEPATOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Excessive Dosing of Obeticholic Acid May Increase Risk of Liver Damage
- (2018) Diane S. Aschenbrenner AMERICAN JOURNAL OF NURSING
- Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model
- (2018) François Briand et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Progress and challenges in the prevention and control of nonalcoholic fatty liver disease
- (2018) Jingjing Cai et al. MEDICINAL RESEARCH REVIEWS
- Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis
- (2018) Kirstine S Tølbøl et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis
- (2018) Sangwon Byun et al. Nature Communications
- Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis
- (2018) Toshihiro Goto et al. Scientific Reports
- FXR modulators for enterohepatic and metabolic diseases
- (2018) Hong Wang et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease
- (2018) Samarth Siddharth Patel et al. DRUGS
- GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
- (2018) Rohit Loomba et al. GASTROENTEROLOGY
- Noncanonical farnesoid X receptor signaling inhibits apoptosis and impedes liver fibrosis
- (2018) Hong Wang et al. EBioMedicine
- Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
- (2018) Jiyu Zhou et al. Acta Pharmaceutica Sinica B
- Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III
- (2017) M. Ghosh Laskar et al. JOURNAL OF INTERNAL MEDICINE
- Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
- (2017) David C. Tully et al. JOURNAL OF MEDICINAL CHEMISTRY
- Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD
- (2017) Valerio Nobili et al. LIVER INTERNATIONAL
- Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
- (2017) Thomas Ruzicka et al. NEW ENGLAND JOURNAL OF MEDICINE
- Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice
- (2017) Hani Jouihan et al. Molecular Metabolism
- Obeticholic Acid: First Global Approval
- (2016) A. Markham et al. DRUGS
- Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters
- (2016) Bin Dong et al. JOURNAL OF LIPID RESEARCH
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- The Bile Acid Receptor TGR5 Activates the TRPA1 Channel to Induce Itch in Mice
- (2014) TinaMarie Lieu et al. GASTROENTEROLOGY
- Bile acids reach out to the spinal cord: New insights to the pathogenesis of itch and analgesia in cholestatic liver disease
- (2014) Paul A. Dawson et al. HEPATOLOGY
- Design, Synthesis, and Biological Evaluation of Potent Dual Agonists of Nuclear and Membrane Bile Acid Receptors
- (2014) Claudio D’Amore et al. JOURNAL OF MEDICINAL CHEMISTRY
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- The TGR5 receptor mediates bile acid–induced itch and analgesia
- (2013) Farzad Alemi et al. JOURNAL OF CLINICAL INVESTIGATION
- Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice
- (2013) Xuelian Xiong et al. JOURNAL OF HEPATOLOGY
- The Bile Acid Sensor FXR Is Required for Immune-Regulatory Activities of TLR-9 in Intestinal Inflammation
- (2013) Barbara Renga et al. PLoS One
- Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside
- (2012) Feng Zhang et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Therapeutic utilities of fibroblast growth factor 19
- (2011) Xinle Wu et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist
- (2010) G. Rizzo et al. MOLECULAR PHARMACOLOGY
- FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats
- (2009) Sabrina Cipriani et al. JOURNAL OF LIPID RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search